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Ever increasing multi-drug resistance by Plasmodium falciparum is creating new challenges in malaria chemothera-
py. In the absence of licensed vaccines, treatment and prevention of malaria is heavily dependent on drugs. Potency, range 
of activity, safety, low cost and ease of administration are crucial issues in the design and formulation of antimalarials. 
We have tested three synthetic ozonides NAC89, LC50 and LCD67 in vitro and in vivo against multidrug resistant Plas-
modium. In vitro, LC50 was at least 10 times more efficient inhibiting P. falciparum multidrug resistant Dd2 strain than 
chloroquine and mefloquine and as efficient as artemisinin (ART), artesunate and dihydroartemisinin. All three ozonides 
showed high efficacy in clearing parasitaemia in mice, caused by multi-drug resistant Plasmodium chabaudi strains, by 
subcutaneous administration, demonstrating high efficacy in vivo against ART and artesunate resistant parasites.
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Artemisinin (ART) and derivatives (ARTs) are the 
sole approved drugs effective against multidrug-resis-
tant parasites (White 2008). ARTs are part of the arte-
misinin combination therapy (ACT’s) protocols, current-
ly recommended by WHO as the first-line treatment for 
uncomplicated Plasmodium falciparum malaria (WHO 
2006, Morris et al. 2010).
However, in addition to the recently detected resis-
tance to ARTs by P. falciparum in Southeast Asia (Don-
dorp et al. 2009, Noedl et al. 2010), ARTs suffer from 
several liabilities that limit their therapeutic potential 
namely, cost, chemical stability, poor bioavailability and 
limiting pharmacokinetics (Avery et al. 1992, Ridley 
2002, Gautam et al. 2009) and recrudescence (White 
1999, Navaratnam et al. 2000).
The pharmacophore of ARTs is an endoperoxide 
bridge also present in trioxolanes (ozonides). Several 
synthetic trioxolanes have been tested for antimalarial 
activity and demonstrated in vivo activity against sus-
ceptible Plasmodium berghei ANKA and in vitro against 
P. falciparum strains (O’Neill et al. 2010).
The aim of the present study was to evaluate the ef-
ficacy of three of these compounds, LC50 (Vennerstrom 
et al. 2004, Dong et al. 2006), LCD67 (Vennerstrom et 
al. 2002) and NAC89 (Vennerstrom et al. 2004, Tang et 
al. 2007) (Supplementary figure 1) in vitro against the 
chloroquine (CQ) and mefloquine (MEF)-resistant P. 
falciparum strain Dd2 (Oduola et al. 1987) and in vivo 
against a multidrug-resistant strain of Plasmodium cha-
baudi (Rosario 1981), AS-ART (Hunt et al. 2010). AS-
ART was derived from a CQ-resistant P. chabaudi (AS-
30CQ) strain under ART pressure (Afonso et al. 2006).
MATERIALS AND METHODS
Synthesis of compounds tested - Details on materials, 
methods and reaction conditions used for the preparation 
of the trioxolanes tested, NAC89, LC50 and LCD67 are 
provided as Supplementary data.
In vitro cytotoxicity assay to human cells - HepG2 
- A16 human hepatic cell line viability was determined 
based on the methyl thiazol tetrazolium method (MTT) 
(Andrade-Neto et al. 2008). Briefly, an in vitro culture 
of HepG2 cells was maintained in standard culture con-
ditions (37ºC, 5% CO2). Cells were seeded in a flat-bot-
tomed 96-well tissue culture plate at a density of 1 × 
104 cells/well and allowed to adhere overnight. After 
removing the medium, 200 μL of fresh medium, con-
taining seven 2-fold dilutions (100000 ng/mL-0.01 ng/
mL) of each compound, were added, and a negative con-
trol was prepared by adding 200 μL of drug free me-
dium. The plate was incubated for 24 h under standard 
culture conditions. The medium was then substituted by 
fresh medium containing identical concentrations of the 
compounds, and the plates were incubated for another 
24 h. At the end of the incubation period (48 h), 20 μL of 
3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazoli-
um [MTT; 5 mg/mL in phosphate buffered saline (PBS)] 
was added to each well, wells were incubated for 3 h at 
standard culture conditions, supernatant was removed, 
and 200 μL of acidified 2-propanol was added to each 
well. Absorbance was read at 570 nm, to produce a log 
dose-dependence curve. The LD50 was estimated for 
each compound by nonlinear interpolation of the dose 
dependence curve using GraphPad Prism 5.
In vitro antimalarial activity - P. falciparum clone 
Dd2 was cultured in human erythrocytes and syn-
chronised twice with D-sorbitol before experiments, 
as described previously (Trager & Jensen 1976). Syn-
chronised parasite cultures at ring stage (with 5% hae-
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matocrit and 1% parasitaemia) were treated for 48 h with 
serial dilutions of NAC89, LC50, LCD67, ART and DHA 
(10 ng/mL-0,156 ng/mL). After this incubation period, 
thin blood smears were prepared from control and treat-
ed wells, fixed with methanol, and Giemsa stained (20% 
Giemsa in buffered water for 20 min). To estimate the 
IC50, the parasitaemia determined for each concentration 
was normalised relative to control wells (no drug added) 
and plotted against the logarithm of the different drug di-
lutions. Corresponding IC50
 
values were estimated from 
dose-response curves generated using GraphPad Prism 5.
Selectivity index (SI) for each compound was determined 
by the ratio between HepG2 LD50 and P. falciparum IC50.
In vivo antimalarial activity - In vivo activity of 
NAC89, LC50 and LCD67, against P. chabaudi strains 
AS-30CQ (sensitive to ART) and AS-ART (resistant to 
ART) selected for ARTs resistance elsewhere (Hunt et 
al. 2010), was assessed by treating infected mice sub-
cutaneously with two different doses (10 and 50 mg/kg/
day, or 2 mg/kg/day for NAC89) of each ozonide, once 
daily, for three consecutive days. Groups of five females 
Balb/C mice, per compound and dose, including PBS as 
negative control. ART was used as a positive control, 
since the profile of antimalarial activity in strains AS-
30CQ and AS-ART was previously known. Parasitae-
mia was monitored in tail blood smears prepared daily, 
fixed with methanol and stained with Giemsa, starting at 
day 4 after first treatment, until day 20. The area under 
the curve (AUC) was estimated using GraphPad Prism 5, 
based on the daily-recorded parasitaemias.
Animals were handled and cared according to the in-
ternationally accepted laboratory animals’ use, care and 
welfare guidelines, in use at IHMT. IHMT’s vivarium 
is licensed by the Portuguese Food and Veterinary Di-
rectorate General for the breeding and use of animals 
(http://www.ihmt.unl.pt/en/vivarium/).
RESULTS AND DISCUSSION
In vitro antimalarial activity - The antimalarial ef-
fect of NAC89, LC50 and LCD67 (Supplementary figure 
1) against P. falciparum blood-stage forms of the CQ and 
mefloquine (MEF) resistant strain Dd2 was evaluated. The 
most active of the compounds was LC50, with an IC50 = 0.8 
± 0.2 ng/mL, followed by NAC89 and LCD67 (Table).
The IC50 values obtained for Dd2 are in line with pre-
vious determinations of in vitro activity against the P. 
falciparum CQ-resistant strain K1 (IC50 = 62.0 ± 4.0 ng/
mL to CQ and 3.0 ± 0.1 ng/mL to MEF) (Vennerstrom et 
al. 2004). When compared to antimalarials in use, LC50 
was as good as ART and better than dihidroartemis-
inin (DHA) inhibiting quinoline-resistant P. falciparum 
blood-stages in vitro. LC50 was 77.5 times more effi-
cient than CQ, 3.7 times more efficient than MEF, 1.4 
times more efficient than DHA and as efficient as ART 
inhibiting quinoline-resistant parasites (Table). Com-
pounds LCD67 and NAC89 also exhibited higher activity 
than CQ and MEF against the quinoline-resistant para-
sites (Dd2). The results indicate that LC50, LCD67 and 
NAC89 do not show cross-resistance with CQ or MEF, 
possibly acting through a different mechanism. In vitro 
cytotoxicity of the compounds NAC89, LC50 and LCD67 
was determined using mammalian HepG2 cells and the 
colorimetric MTT. The resulting LD50s indicate that the 
compounds tested have very low cytotoxicity (Table).
The three compounds demonstrated exceptional 
growth-inhibitory activities against multi-drug resist-
ance P. falciparum parasites (in the nanomolar range), 
while showing neglectable effect on the growth or via-
bility of mammalian cells (SI ≥ 11000) (Table), this indi-
cating an ample therapeutic window.
In vivo antimalarial activity of LC50, LCD67 and 
NAC89 - Even though NAC89 exhibited the second best 
SI (still very high), at the dose of 50 mg/kg/day two mice 
TABLE
In vitro evaluation of cytotoxicity in HepG2 and activity of new ozonides against chloroquine and mefloquine resistant  
Plasmodium falciparum and in vivo activity against artemisinin resistant Plasmodium chabaudi strains in three different doses
In vitro In vivo
Compound
P. falciparum
(Dd2)
Cell line 
HepG2
SI
(P. chabaudi)
AS-30CQ (mg/kg)
(P. chabaudi)
AS-ART (mg/kg)
IC50 (ng/mL) LD50 (ng/mL)
2 10 50 2 10 50
AUC (mean ± sem) AUC (mean ± sem)
PBS - - - 111.8 ± 15.6 99.6 ± 33.7
LC50 0.8 ± 0.2 31841.0 39801.2 - 7.6 ± 2.1 0 - 58.0 ± 16.5 6.7 ± 2.0
LCD67 2.0 ± 0.1 23576.0 11788.0 - 109.9 ± 18.9 15.2 ± 4.1 - 40.5 ±17.5 29.2 ± 2.9
NAC89 1.7 ± 0.2 53818.0 31657.6 29.6 ± 7.6 7.9 ± 4.5 - 32.0 ± 7,9 8.3 ± 2.7 -
ART 0.7 ± 0.1 - - - 51.8 ± 14.5 11.9 ± 4.5 89.6 ± 16.4 24.7 ± 3.8
DHA 1.1 ± 0.2 - - - - - - - -
ART: artemisinin; AUC: area under the curve; CQ: chloroquine; DHA: dihidroartemisinin; IC50: inhibitory concentration for 
50% of the parasites; LD50: lethal dose to 50% of the cells; PBS: phosphate buffered saline; SI: selective index.
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exhibited a small lesion at the injection site, which was 
not observed with the dose of 10 mg/kg/day. Therefore, 
to be able to test for dose response effect, a second dose 
of 2 mg/kg/day was used. It is currently accepted that 
the phenotype of ART drug resistance is reflected by the 
increased parasitaemia clearance time. Additionally, P. 
chabaudi strains with an AS genetic background are not 
lethal, mice resolve infection in ~ 20 days without treat-
ment (Bagnaresi et al. 2009). Mean of all measurements, 
height of peak, time to reach peak and time to return to 
baseline level are the usual parameters to express the ef-
ficacy of compounds (Matthews et al. 1990). By defini-
tion, the AUC is a summary calculation used when serial 
measurements on each subject under study are carried 
out. We propose the AUC to express the evolution of the 
parasitaemia after treatment, as a more biologically rel-
evant estimator, because it incorporates both the mag-
nitude and the duration of parasitaemia patency. Thus, 
parasitaemia evolution after treatment was monitored 
and expressed as AUC (Table). AUCs reflecting antima-
larial activity of control drug (ART) against both AS-
30CQ and AS-ART P. chabaudi clones were calculated 
(Supplementary figure 2). The AUC value for the ART- 
sensitive strain (AS-30CQ) was significantly lower than 
the AUC for the resistant one (AS-ART) as compared by 
the two-sided Mann-Whitney test (p < 0.001).
When compared to the untreated control (PBS with 
10% DMSO), ART produced a significant reduction in 
parasitaemia and a dose response effect. The AUC val-
ues reflected the expected phenotype described else-
where (Hunt et al. 2010).
In both resistant and sensitive strains, when com-
pared to the untreated control, LC50 and NAC89 in-
duced a significant reduction of the AUC (p < 0.001) at 
both doses, while the LCD67 only caused a significant 
reduction at a dose of 50 mg/kg (p < 0.001). Considering 
the three trioxolanes and ART, NAC89 was the most ac-
tive against the AS-ART since even at a dose as low as 
10 mg/kg the AUCs were significantly lower (p < 0.01) 
(Supplementary figure 3, Table).
When compared to equivalent doses of the control 
drug ART, all three tested ozonides followed the same 
pattern, reducing 1.5 -11.0 times the correspondent AUC. 
When compared with ART, the LC50 compound showed 
better antimalarial activity at both doses, against both (AS-
30CQ and AS-ART) strains. At the highest dose (50 mg/
kg), LC50 reduced the parasitaemia 3.7 and 11.9 times on 
the resistant and sensitive strains, respectively. At the low-
est concentration (10 mg/kg), the reduction was 1.5 and 
6.8 times, respectively. LC50 had already demonstrated in 
vivo activity against P. berghei ANKA (drug susceptible 
strain) when administrated subcutaneously in a dose of 
100 mg/kg (survival up to 30 days) and orally (100 mg/kg, 
survival up to 10.7 days) (Vennerstrom et al. 2004).
In conclusion, the compounds tested showed an ex-
cellent antimalarial activity in vitro and in vivo against 
resistant strains. Although NAC89 needs further toxicity 
evaluations, the other ozonides LC50 and LCD67 exhib-
ited an excellent performance in vitro, against a multid-
rug resistant P. falciparum strain, and in vivo, against a 
CQ-resistant and ART-resistant rodent malaria strains. 
The high SI of all three compounds against Plasmodium 
parasites compared to mammalian cells, as well as their 
potent in vivo activity against resistant strains of rodent 
malaria parasites (P. chabaudi), suggest that this class of 
compounds deserves further investigation.
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